This Article Full Text Full Text (PDF) All Versions of this Article: 29/1/76    most recent Final Manuscript Author Manuscript Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Biondi, B. Articles by Cooper, D. S. Search for Related Content PubMed PubMed Citation Articles by Biondi, B. Articles by Cooper, D. S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB LEVOTHYROXINE LIOTHYRONINE Medline Plus Health Information Thyroid Diseases

The Clinical Significance of Subclinical Thyroid Dysfunction

Department of Clinical and Molecular Endocrinology and Oncology (B.B.), University of Naples Federico II, 80131 Naples, Italy; and Sinai Hospital of Baltimore (D.S.C.), The Johns Hopkins University School of Medicine, Baltimore, Maryland 21215

Correspondence: Address all correspondence and requests for reprints to: Bernadette Biondi, Department of Clinical and Molecular Endocrinology and Oncology, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy. E-mail: bebiondi{at}unina.it or bebiondi{at}libero.it

Subclinical thyroid disease (SCTD) is defined as serum free T₄ and free T₃ levels within their respective reference ranges in the presence of abnormal serum TSH levels. SCTD is being diagnosed more frequently in clinical practice in young and middle-aged people as well as in the elderly. However, the clinical significance of subclinical thyroid dysfunction is much debated. Subclinical hyper- and hypothyroidism can have repercussions on the cardiovascular system and bone, as well as on other organs and systems. However, the treatment and management of SCTD and population screening are controversial despite the potential risk of progression to overt disease, and there is no consensus on the thyroid hormone and thyrotropin cutoff values at which treatment should be contemplated. Opinions differ regarding tissue effects, symptoms, signs, and cardiovascular risk. Here, we critically review the data on the prevalence and progression of SCTD, its tissue effects, and its prognostic implications. We also examine the mechanisms underlying tissue alterations in SCTD and the effects of replacement therapy on progression and tissue parameters. Lastly, we address the issue of the need to treat slight thyroid hormone deficiency or excess in relation to the patient’s age.

This article has been cited by other articles:

				H. Kumar K. V. S., A. Verma, J. Muthukrishnan, and K. D. Modi Obesity and Hypothyroidism: Symbiotic Coexistence Arch Intern Med, October 27, 2008; 168(19): 2168 - 2168. [Full Text] [PDF]

				B. Biondi Should we treat all subjects with subclinical thyroid disease the same way? Eur. J. Endocrinol., September 1, 2008; 159(3): 343 - 345. [Full Text] [PDF]

				M. Chonchol, G. Lippi, G. Salvagno, G. Zoppini, M. Muggeo, and G. Targher Prevalence of Subclinical Hypothyroidism in Patients with Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1296 - 1300. [Abstract] [Full Text] [PDF]

				S. Mariotti Mild Hypothyroidism and Ischemic Heart Disease: Is Age the Answer? J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 2969 - 2971. [Full Text] [PDF]

				S. Razvi, A. Shakoor, M. Vanderpump, J. U. Weaver, and S. H. S. Pearce The Influence of Age on the Relationship between Subclinical Hypothyroidism and Ischemic Heart Disease: A Metaanalysis J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 2998 - 3007. [Abstract] [Full Text] [PDF]